Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Immunomodulation with pomalidomide in AML and high-risk MDS

Joshua Zeidner • 8 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Pomalidomide

Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, discusses immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Joshua Zeidner

5:13
Phase II trial of pembrolizumab prior to allo-SCT in AML
Joshua Zeidner • 25 Nov 2020
4:57
The impact of pevonedistat on patient-reported outcomes in the P-2001 study
Joshua Zeidner • 25 Nov 2020
5:08
Zella 201: alvocidib-based regimens in MCL-1 dependent high-risk AML
Joshua Zeidner • 25 Nov 2020
6:20
ZELLA 101: alvocidib for newly diagnosed AML
Joshua Zeidner • 8 Jun 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals